# Oral 25-hydroxyvitamin D3 and COVID-19

> **NCT04386850** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Tehran University of Medical Sciences** · enrollment: 1500 (estimated)

## Conditions studied

- COVID 19

## Interventions

- **DRUG:** Oral 25-Hydroxyvitamin D3

## Key facts

- **NCT ID:** NCT04386850
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-14
- **Primary completion:** 2020-11-15
- **Final completion:** 2021-03-15
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2020-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04386850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04386850, "Oral 25-hydroxyvitamin D3 and COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04386850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*